Quantified Mobile Sensing for Improving Diagnosis and Measuring Disease Progression
Completed
- Conditions
- Bipolar DisorderDepression
- Interventions
- Other: Cogito Companion Mobile Phone Application
- Registration Number
- NCT02742064
- Lead Sponsor
- Cogito Health Inc
- Brief Summary
The purpose of this study is to determine if a mobile sensing platform can passively and objectively detect the presence of clinically significant mood disorder symptomatology and symptom progression over time. Meeting this goal will allow for improved risk categorization, prediction of relapse, and measurement of disease progression in a lifetime prevalence population.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 899
Inclusion Criteria
- Age 18 or older
- Have a smartphone and cell service plan, including voice and data, that meets the device requirements of the Mobile Sensing Platform.
- Enrolled in the MoodNetwork
Exclusion Criteria
- Report positively on the QIDS-SR suicide item during study intake
- Total score greater than 15 on the QIDS-SR during the screening process
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description MDD-Recurrent Cogito Companion Mobile Phone Application 1. Subjects who have experienced 2 or more episodes of depressive disorder (MDD) in their lifetime. MDD-Single Episode Cogito Companion Mobile Phone Application 1. Subjects who have experienced 1 episode of major depressive disorder (MDD) in their lifetime. Bipolar Disorder Cogito Companion Mobile Phone Application 1. Subjects who have been diagnosed with bipolar disorder in their lifetime.
- Primary Outcome Measures
Name Time Method Severity of Mania symptoms as assessed by ASRM 6 months Severity of MDD symptoms as assessed by QIDS SR 6 months
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Massachusetts General Hospital
🇺🇸Boston, Massachusetts, United States